Eli Kammerman - Masimo Investor Relations Officer
| MASI Stock | USD 177.95 1.81 1.03% |
Executive
Eli Kammerman is Investor Relations Officer of Masimo since 2013.
| Tenure | 11 years |
| Address | 52 Discovery, Irvine, CA, United States, 92618 |
| Phone | 949 297 7000 |
| Web | https://www.masimo.com |
Masimo Management Efficiency
The company has return on total asset (ROA) of 0.0266 % which means that it generated a profit of $0.0266 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0574 %, meaning that it created $0.0574 on every $100 dollars invested by stockholders. Masimo's management efficiency ratios could be used to measure how well Masimo manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Masimo's Return On Tangible Assets are decreasing as compared to previous years. The Masimo's current Return On Capital Employed is estimated to increase to 0.14, while Return On Assets are projected to decrease to 0.04. As of now, Masimo's Other Current Assets are increasing as compared to previous years. The Masimo's current Total Current Assets is estimated to increase to about 1.3 B, while Other Assets are projected to decrease to under 327.8 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| June Lazaroff | Insulet | N/A | |
| Ahmet Tezel | LivaNova PLC | N/A | |
| Gerardo Hernandez | TransMedics Group | N/A | |
| Shelly Selvaraj | DexCom Inc | 65 | |
| Leverne Marsh | DexCom Inc | N/A | |
| Teri Lawver | DexCom Inc | 57 | |
| Hollie Foust | CONMED | N/A | |
| Mark Novara | Tandem Diabetes Care | 49 | |
| Angela Ahmad | Inari Medical | N/A | |
| Paul Koehn | Inari Medical | 61 | |
| Trang Ly | Insulet | N/A | |
| Karen Silva | Inari Medical | N/A | |
| Kimberly Lockwood | CONMED | N/A | |
| John Borrell | Inari Medical | 57 | |
| Shacey Petrovic | Insulet | 51 | |
| Nick Corcoran | TransMedics Group | 42 | |
| Angela Wiczek | Insulet | N/A | |
| Bryan Olin | LivaNova PLC | 57 | |
| Richard Glaze | CONMED | 58 | |
| Shannon Hansen | Tandem Diabetes Care | 58 | |
| Stacey Stewart | DexCom Inc | N/A | |
Management Performance
| Return On Equity | 0.0574 | ||||
| Return On Asset | 0.0266 |
Masimo Leadership Team
Elected by the shareholders, the Masimo's board of directors comprises two types of representatives: Masimo inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Masimo. The board's role is to monitor Masimo's management team and ensure that shareholders' interests are well served. Masimo's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Masimo's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Blair Tripodi, Chief Division | ||
| Yongsam Lee, CIO and Executive VP | ||
| Tetsuro Maniwa, President Japan | ||
| Steven Barker, Chairman Officer | ||
| Micah Young, CFO, Executive Vice President | ||
| Tao Levy, Executive Vice President - Business Development | ||
| Micah CPA, Executive CFO | ||
| Eli Kammerman, Investor Relations Officer | ||
| Jon Coleman, President - Worldwide Sales, Professional Services and Medical Affairs | ||
| Joseph Kiani, Chairman of the Board, CEO | ||
| Thomas McClenahan, General VP | ||
| Michelle Brennan, Interim Director | ||
| Paul Hataishi, Senior Officer | ||
| Bilal Muhsin, Executive Vice President Engineering, Marketing & Regulatory Affairs | ||
| Thomas JD, General VP | ||
| Anand Sampath, Executive Research |
Masimo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Masimo a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0574 | ||||
| Return On Asset | 0.0266 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 10.13 B | ||||
| Shares Outstanding | 53.54 M | ||||
| Shares Owned By Insiders | 8.18 % | ||||
| Shares Owned By Institutions | 94.90 % | ||||
| Number Of Shares Shorted | 3.2 M | ||||
| Price To Earning | 35.69 X |
Currently Active Assets on Macroaxis
When determining whether Masimo offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Masimo's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Masimo Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Masimo Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Masimo. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Masimo Stock please use our How to Invest in Masimo guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Masimo. If investors know Masimo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Masimo listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.10) | Earnings Share 1.44 | Revenue Per Share 38.467 | Quarterly Revenue Growth 0.054 | Return On Assets 0.0266 |
The market value of Masimo is measured differently than its book value, which is the value of Masimo that is recorded on the company's balance sheet. Investors also form their own opinion of Masimo's value that differs from its market value or its book value, called intrinsic value, which is Masimo's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Masimo's market value can be influenced by many factors that don't directly affect Masimo's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Masimo's value and its price as these two are different measures arrived at by different means. Investors typically determine if Masimo is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Masimo's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.